Debbie Rigby takes a look at the latest in research news
In a large placebo-controlled randomized trial, pantoprazole was not associated with any adverse event when used for 3 years, with the possible exception of an increased risk of enteric infections. C difficile infection was approximately twice as common in the pantoprazole vs the placebo group, although there were only 13 events, so this difference was not statistically significant.
People with OA are more likely to have other chronic conditions. A systematic review and meta‐analysis of observational studies shows key comorbidities associated with OA are stroke, peptic ulcer and metabolic syndrome. The association is dose‐dependent in terms of the number of comorbidities, suggesting multimorbidities.
Arthritis Care & Research 2019.
A cochrane review of 21 RCTs has concluded that tramadol alone or in combination with paracetamol probably has no important benefit on mean pain or function in people with osteoarthritis. Moderate quality evidence shows that adverse events, such as nausea, dizziness and tiredness probably cause substantially more participants to stop taking tramadol.
Cochrane Database of Systematic Reviews 2019, Issue 5.
This article discusses the recommended investigations to aid diagnosis and the role of pharmacotherapy in the management of chronic heart failure. All patients with heart failure with reduced ejection fraction (HFrEF) should be prescribed an angiotensin-converting enzyme (ACE) inhibitor (for inhibition of the RAAS system), and a beta-blocker such as carvedilol or bisoprolol. Where an ACE inhibitor is not tolerated, an angiotensin II-receptor blocker (ARB) or angiotensin receptor-neprilysin inhibitor (ARNI – see below) can be used instead. Each of these medications should be titrated to the maximum tolerated dose.